jm6b01266_si_002.csv (2.29 kB)
Synthesis of Novel c(AmpRGD)–Sunitinib Dual Conjugates as Molecular Tools Targeting the αvβ3 Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis
dataset
posted on 2016-12-06, 00:00 authored by Andrea Sartori, Elisabetta Portioli, Lucia Battistini, Lido Calorini, Alberto Pupi, Federica Vacondio, Daniela Arosio, Francesca Bianchini, Franca ZanardiOn the basis of a previously discovered
anti-αVβ3 integrin peptidomimetic
(c(AmpRGD)) and the clinically
approved antiangiogenic kinase inhibitor sunitinib, three novel dual
conjugates were synthesized (compounds 1–3), featuring the covalent and robust linkage between these
two active modules. In all conjugates, the ligand binding competence
toward αVβ3 (using both isolated
receptors and αVβ3-overexpressing
endothelial progenitor EP cells) and the kinase inhibitory activity
(toward both isolated kinases and EPCs) remained almost untouched
and comparable to the activity of the single active units. Compounds 1–3 showed interesting antiangiogenesis
properties in an in vitro tubulogenic assay; furthermore, dimeric-RGD
conjugate 3 strongly inhibited in vivo angiogenesis in
Matrigel plug assays in FVB mice. These results offer proof-of-concept
of how the covalent conjugation of two angiogenesis-related small
modules may result in novel and stable molecules, which impair tumor-related
angiogenesis with equal or even superior ability as compared to the
single modules or their simple combinations.
History
Usage metrics
Categories
Keywords
antiangiogenesis propertiesEPCMolecular Tools Targetingdimeric-RGD conjugate 3covalent conjugationImpairing Tumor-Associated Angiogenesistubulogenic assayligand binding competencemoduletumor-related angiogenesisantiangiogenic kinase inhibitor sunitinib-α V β 3 integrin peptidomimeticvivo angiogenesisMatrigel plug assaysα V β 3progenitor EP cellsresults offer proof-of-conceptFVB mice
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC